PL374019A1 - Pochodne benzoksazyny jako modulatory 5-HT6 i ichzastosowanie - Google Patents

Pochodne benzoksazyny jako modulatory 5-HT6 i ichzastosowanie

Info

Publication number
PL374019A1
PL374019A1 PL03374019A PL37401903A PL374019A1 PL 374019 A1 PL374019 A1 PL 374019A1 PL 03374019 A PL03374019 A PL 03374019A PL 37401903 A PL37401903 A PL 37401903A PL 374019 A1 PL374019 A1 PL 374019A1
Authority
PL
Poland
Prior art keywords
sup
modulators
benzoxazine derivatives
compounds
formula
Prior art date
Application number
PL03374019A
Other languages
English (en)
Other versions
PL211057B1 (pl
Inventor
Jacob Berger
Robin Douglas Clark
Shu-Hai Zhao
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL374019A1 publication Critical patent/PL374019A1/pl
Publication of PL211057B1 publication Critical patent/PL211057B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Wynalazek dotyczy związków o wzorze (I), w którym R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, Y, Z<sup>1</sup>, m, n i p mają znaczenie podane w opisie, oraz ich farmaceutycznie dopuszczalnych soli i proleków wykazujących powinowactwo do receptora 5-HT6. Wynalazek dotyczy także środków zawierających te związki, sposobów stosowania i sposobów wytwarzania związków o wzorze (I).
PL374019A 2002-05-13 2003-05-05 Pochodne benzoksazyny, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych benzoksazyny PL211057B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37800302P 2002-05-13 2002-05-13

Publications (2)

Publication Number Publication Date
PL374019A1 true PL374019A1 (pl) 2005-09-19
PL211057B1 PL211057B1 (pl) 2012-04-30

Family

ID=29420358

Family Applications (1)

Application Number Title Priority Date Filing Date
PL374019A PL211057B1 (pl) 2002-05-13 2003-05-05 Pochodne benzoksazyny, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych benzoksazyny

Country Status (36)

Country Link
US (4) US6867204B2 (pl)
EP (1) EP1506179B1 (pl)
JP (1) JP4307377B2 (pl)
KR (1) KR100636475B1 (pl)
CN (1) CN100429206C (pl)
AR (1) AR039988A1 (pl)
AT (1) ATE316523T1 (pl)
AU (1) AU2003233231B2 (pl)
BR (1) BRPI0310032B8 (pl)
CA (1) CA2485136C (pl)
DE (1) DE60303376T2 (pl)
DK (1) DK1506179T3 (pl)
EA (1) EA009982B1 (pl)
EC (1) ECSP045420A (pl)
EG (1) EG25683A (pl)
ES (1) ES2256744T3 (pl)
GT (1) GT200300108A (pl)
HR (1) HRP20041030B1 (pl)
IL (1) IL164928A0 (pl)
JO (1) JO2413B1 (pl)
MA (1) MA27118A1 (pl)
MX (1) MXPA04011254A (pl)
MY (1) MY139612A (pl)
NO (1) NO329380B1 (pl)
NZ (1) NZ536230A (pl)
PA (1) PA8573501A1 (pl)
PE (1) PE20040757A1 (pl)
PL (1) PL211057B1 (pl)
PT (1) PT1506179E (pl)
RS (1) RS51042B (pl)
TN (1) TNSN04225A1 (pl)
TW (1) TWI258479B (pl)
UA (1) UA76877C2 (pl)
UY (1) UY27803A1 (pl)
WO (1) WO2003095434A1 (pl)
ZA (1) ZA200408783B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2323451T7 (es) 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
RU2309154C9 (ru) 2002-03-27 2016-09-27 Глэксо Груп Лимитед 3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты)
PT1506179E (pt) * 2002-05-13 2006-06-30 Hoffmann La Roche Derivados de benzoxazina como moduladores de 5-ht6 e suas utilizacoes
PL377770A1 (pl) * 2002-11-08 2006-02-20 F. Hoffmann-La Roche Ag Podstawione benzoksazynony i ich zastosowanie
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
ATE371653T1 (de) * 2003-12-09 2007-09-15 Hoffmann La Roche Benzoxazinderivate und deren verwendungen
JP4533391B2 (ja) * 2004-01-16 2010-09-01 エフ．ホフマン−ラ ロシュ アーゲー 中枢神経系疾患の処置のための５−ヒドロキシトリプタミンレセプター（５−ｈｔ）のモジュレーターとしての、１−ベンジル−５−ピペラジン−１−イル−３，４−ジヒドロ−１ｈ−キナゾリン−２−オン誘導体、ならびにそれぞれの１ｈ−ベンゾ（１，２，６）チアジアジン−２，２−ジオキシドおよび１，４−ジヒドロベンゾ（ｄ）（１，３）オキサジン−２−オン誘導体
CA2566196A1 (en) * 2004-05-05 2005-11-10 F. Hoffmann-La Roche Ag Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5-ht2a receptor or both
CN102114244A (zh) * 2004-09-30 2011-07-06 弗·哈夫曼-拉罗切有限公司 治疗认知障碍的组合物和方法
US7378415B2 (en) * 2004-09-30 2008-05-27 Roche Palo Alto Llc Benzoxazine and quinoxaline derivatives and uses thereof
NZ553848A (en) * 2004-09-30 2010-01-29 Hoffmann La Roche Benzoxazine and quinoxaline derivatives and their use in treating diseases associated with the central nervous system
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
AR078770A1 (es) * 2009-10-27 2011-11-30 Elara Pharmaceuticals Gmbh Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
KR101293384B1 (ko) * 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
US9403800B2 (en) * 2012-01-24 2016-08-02 Chemregen, Inc. Compounds for inhibition of cancer cell proliferation
US10087151B2 (en) 2014-01-09 2018-10-02 The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1029479C (zh) * 1989-11-08 1995-08-09 山之内制药株式会社 新型苯并噁嗪衍生物的制备方法
US5492914A (en) * 1994-07-28 1996-02-20 Syntex (U.S.A.) Inc. 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
EP0975593A1 (en) 1997-04-18 2000-02-02 Smithkline Beecham Plc Indole derivatives having combined 5ht1a, 5ht1b and 5ht1d receptor antagonist activity
EP0994862B1 (en) 1997-07-11 2005-06-01 SmithKline Beecham plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
KR100545329B1 (ko) * 1997-07-25 2006-01-24 하. 룬트벡 아크티에 셀스카브 인돌 및 2,3-디히드로인돌 유도체, 그들의 제조방법 및 사용
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
HUP0101475A3 (en) * 1998-06-19 2003-01-28 Lundbeck & Co As H 4,5,6 and 7-indole and indoline derivatives, their preparation and use
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
WO2001014330A2 (en) * 1999-08-23 2001-03-01 Solvay Pharmaceuticals B.V. Phenylpiperazines as serotonin reuptake inhibitors
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
WO2001057003A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
PT1506179E (pt) * 2002-05-13 2006-06-30 Hoffmann La Roche Derivados de benzoxazina como moduladores de 5-ht6 e suas utilizacoes

Also Published As

Publication number Publication date
US20030232825A1 (en) 2003-12-18
EP1506179A1 (en) 2005-02-16
WO2003095434A1 (en) 2003-11-20
JP4307377B2 (ja) 2009-08-05
JP2005530774A (ja) 2005-10-13
US20130123251A1 (en) 2013-05-16
US20050130962A1 (en) 2005-06-16
BR0310032A (pt) 2005-02-15
ZA200408783B (en) 2005-12-28
CA2485136C (en) 2011-12-20
BRPI0310032B1 (pt) 2019-01-08
PT1506179E (pt) 2006-06-30
ES2256744T3 (es) 2006-07-16
EP1506179B1 (en) 2006-01-25
KR20040106538A (ko) 2004-12-17
ECSP045420A (es) 2005-01-03
KR100636475B1 (ko) 2006-10-18
EA200401455A1 (ru) 2005-06-30
HK1080846A1 (zh) 2006-05-04
TW200400188A (en) 2004-01-01
GT200300108A (es) 2004-03-15
UA76877C2 (uk) 2006-09-15
TWI258479B (en) 2006-07-21
RS51042B (sr) 2010-10-31
MY139612A (en) 2009-10-30
NO20044665L (no) 2004-12-03
EG25683A (en) 2012-05-16
EA009982B1 (ru) 2008-04-28
AU2003233231B2 (en) 2009-02-26
DK1506179T3 (da) 2006-06-06
HRP20041030B1 (hr) 2013-03-31
US6867204B2 (en) 2005-03-15
MXPA04011254A (es) 2005-01-25
DE60303376D1 (de) 2006-04-13
NZ536230A (en) 2007-05-31
JO2413B1 (en) 2007-11-11
CA2485136A1 (en) 2003-11-20
TNSN04225A1 (fr) 2007-03-12
PA8573501A1 (es) 2003-12-10
MA27118A1 (fr) 2004-12-20
PE20040757A1 (es) 2004-11-06
ATE316523T1 (de) 2006-02-15
DE60303376T2 (de) 2006-11-16
UY27803A1 (es) 2003-11-28
AU2003233231A1 (en) 2003-11-11
HRP20041030A2 (en) 2005-06-30
IL164928A0 (en) 2005-12-18
BRPI0310032B8 (pt) 2021-05-25
RS97004A (sr) 2006-10-27
NO329380B1 (no) 2010-10-04
PL211057B1 (pl) 2012-04-30
AR039988A1 (es) 2005-03-09
US8377931B2 (en) 2013-02-19
CN1653054A (zh) 2005-08-10
CN100429206C (zh) 2008-10-29
US20090325950A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
PL374019A1 (pl) Pochodne benzoksazyny jako modulatory 5-HT6 i ichzastosowanie
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
BG107171A (bg) Производни на пурин
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
SE0302760D0 (sv) New compounds
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
PA8621501A1 (es) Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la síntesis de los mismos
MX2007012883A (es) Derivados de dihidrobenzofurano y usos de los mismos.
CA2511255A1 (en) 2-piperidone derivatives as prostaglandin agonists
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
MX2007012936A (es) Derivados de dihidrobenzofurano y usos de los mismos.
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
MY136824A (en) Substituted benzoxazinones and uses thereof
HRP20050213A2 (en) 2,4-substituted indoles and their use as 5-ht6 modulators
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
DK1406902T3 (da) Hexahydroazepino[4,5-g]indoler og -indoliner som 5-HT-receptor-ligander
PL1831191T3 (pl) Pochodne chromanu i ich zastosowanie jako ligandów receptorów 5-HT
DE602004016177D1 (de) Methylindole und methylpyrrolopyridine als alpha-1-adrenerge agonisten
IL188927A0 (en) Aryloxy quinolines and uses thereof as 5-ht6 modulators
ATE246174T1 (de) Tosylprolin-derivate als thymidylat-synthase inhibitoren

Legal Events

Date Code Title Description
T3 Translation of ep patent
RECP Rectifications of patent specification